AV2_2847AV2_2847

The Tevosol team after winning the DynaLife Health Stream at the 15th VenturePrize Awards

A patent acceptance in the US is the most recent reason to celebrate after a year of successes for Tevosol, a medical device company aiming to increase the number of viable donated organs worldwide. In the last 12 months, Tevosol secured $2 million in financing, won the DynaLIFE Health Stream at the VenturePrize awards, and protected its technology in the US.

Tevosol’s proprietary medical device keeps donated vital organs like hearts and lungs, warm and supplied with oxygen as if they were still in the body, extending the “ex-vivo” (out of body) viability of the organs. The device also resuscitates organs deemed unsuitable, and allows assessment of transplant suitability which has the potential to double or triple the number of available donor organs worldwide.

The recently accepted patent refers to Tevosol’s heart device, and protects the core technology that provides a functional assessment of organs for viability.

A key element to the device (and the patent) is the way the dual centrifugal pumps work. “The proprietary configuration of the pumps is essential to put the heart into functional working mode, and to the ability to assess the quality of the organ,” explains Tevosol CEO Kevin Ens. “That’s the unique way we do things that our competitors are not.”

The company is developing a clinical device incorporating the technology that covers the patent. Kevin expects to have a beta version developed by late 2019, and estimates a Canadian market launch by 2021, and a US launch one year later.

“This is the first foundational patent for us,” says Kevin. “Assuming other applications are granted, we would expect another patent to be issued extending IP protection to different organs, and more patent families that add protection for our other technology. This one is key.”

Tevosol has been a TEC Edmonton client since the beginning of the company’s original business plan in 2014. TEC’s business development services accelerated Tevosol’s growth into an independent company through assistance with market assessment, business planning, patenting, and intellectual property (IP) protection. Tevosol is a TEC Centre tenant, operating out of Enterprise Square in downtown Edmonton.

Posted: Apr 3, 2019

A Novel Method to Produce Pitched Kefir for Reducing Cholesterol

Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......


Posted: Nov 5, 2018

Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging

Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......


Posted: Nov 5, 2018

A Novel Method for CryoPreservation of Cells in Monolayers

Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......


Posted: Oct 30, 2018

Train-Triggered Alert System for Conditioning and Warning Wildlife

Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......


Posted: Oct 19, 2018

New Topical Therapy for Melanoma

Description Dr. Afsaneh Lavasanifar and collaborators have developed a PCBCL–b-PEG-b-PCBCL (PolyGelTM) hydrogel formulation of silibinin which provides enhanced skin permeabiity and delayed release of silibinin under physiological conditions. In vitro......


Posted: Aug 2, 2018

Novel FOXM-1 inhibitors for diagnosis and treatment of cancer

Description Researchers at the University of Alberta are utilizing their new insights into the mechanism of action of FOXM-1 inhibitors to design first in class oncology drugs targeting FOXM-1 protein.......


Posted: Aug 2, 2018

Novel SERS-Based Biosensing platform for prostate cancer

Description Researchers at the University of Alberta have developed biogenic silver nanoparticles which can be used as plasmonic labels for enhanced spectroscopy applications. The nanoparticles can be modified with Raman......


Posted: Mar 29, 2018

Hand-Held Device and Computer-Implemented Steering of a Percutaneously Inserted Needle

Description Dr. Mahdi Tavakoli and his team at the University of Alberta have developed a novel hand-held device and methods to enable real-time assisted steering of percutaneously inserted needles, such as......


Posted: Mar 20, 2018

Novel Radiation-Responsive Nanoparticles for Biomedical Applications

Description Researchers at the University of Alberta in collaboration with Lakehead University have developed novel radiation-responsive block polymers for drug delivery. The nanoparticles are modified poly-L-glutamic acid (m-PGA) polymers which......


Posted: Mar 13, 2018

Flow Cytometry Sensing Using Diffracted Orders of a Grating

Description Flow cytometry is a useful tool that employed in diagnoses of various blood diseases, basic research, clinical trials or even as a “cell sorter” instrument. Currently, flow cytometry involves......


Posted: Mar 13, 2018

Off-Axis Spiral Phase Mirrors To Create Vortex Beams

Description There has been an increased interest in taking advantage of the orbital angular momentum properties of light via helical wavefronts for various applications in manufacturing, imaging, and communications. By......


Posted: Mar 6, 2018

Allyl Monomers And Polymers From Glycerol

Description In recent years, with the rapid expansion in biodiesel production, the biodiesel industry is facing the dilemma, on the one hand, of how to meet an ever-growing biofuel demand,......